Rein Therapeutics, Inc. - חוב לטווח קצר להון RNTX

Rein Therapeutics Inc (RNTX) management is currently restructuring following the consolidation of assets while grappling with a liquidity shortage. This chart shows the market price on GURU.Markets, which stands at 0.00, correlating with the interest of chemists in developing targeted cancer drugs. Meanwhile, the company relies on outsourcing all production, which minimizes its environmental impact.

To assess the financial stability of Rein Therapeutics Inc (RNTX), it is critical to monitor the level of short-term liabilities relative to equity. This indicator measures the share of debt maturing within one year, while the current ratio of short-term loans to equity allows for an assessment of the company's liquidity required to fund the development of a broad portfolio of orphan disease drugs and minimize drawdown risks.